BioMerieux SA

EYWN

Company Profile

  • Business description

    BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.

  • Contact

    Marcy l’Etoile
    Lyon69280
    FRA

    T: +33 478872000

    E: [email protected]

    https://www.biomerieux.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2026

    Employees

    15,226

Stocks News & Analysis

stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.
stocks

Chart of the Week: Anthropic’s IPO range sits below our fair value

Our fair value is above the IPO range, but outcomes could differ widely.
stocks

Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released

Several gaming shares are trading at a discount to our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,849.7082.70-0.93%
CAC 408,146.8369.95-0.85%
DAX 4025,736.24309.13-1.19%
Dow JONES (US)50,198.17561.25-1.11%
FTSE 10010,551.17138.70-1.30%
HKSE22,823.43471.32-2.02%
NASDAQ24,429.88101.500.42%
Nikkei 22559,140.87116.590.20%
NZX 50 Index14,263.570.72-0.01%
S&P 5007,323.6316.90-0.23%
S&P/ASX 2008,744.2077.60-0.88%
SSE Composite Index3,550.3737.46-1.04%

Market Movers